US FDA expands use of Amgen, AstraZeneca's drug for sinus infection
1. FDA approves Amgen and AstraZeneca's drug for chronic sinus infection.
FAQ
Why Bullish?
FDA approval can lead to increased market share and revenue growth for AMGN, as evidenced by previous launches like Aimovig and their significant impacts on stock performance.
How important is it?
The FDA approval is a positive development that can influence investor sentiment and stock price amidst ongoing profitability concerns in biotech.
Why Short Term?
Initial revenue from the new drug can be seen within a year, similar to past drug approvals enhancing AMGN's financial outlook.